Cutting-Edge Therapeutics Limited - Filleted accounts

Cutting-Edge Therapeutics Limited - Filleted accounts


Cutting-Edge Therapeutics Limited
Registered number: 10146338
Balance Sheet
as at 30 April 2021
Notes 2021 2020
£ £
Fixed assets
Tangible assets 3 1,464 1,466
Current assets
Debtors 4 429 -
Cash at bank and in hand 18,218 12,440
18,647 12,440
Creditors: amounts falling due within one year 5 (12,818) (9,085)
Net current assets 5,829 3,355
Net assets 7,293 4,821
Capital and reserves
Called up share capital 100 100
Profit and loss account 7,193 4,721
Shareholders' funds 7,293 4,821
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Zahid Sattar
Director
Approved by the board on 21 January 2022
Cutting-Edge Therapeutics Limited
Notes to the Accounts
for the year ended 30 April 2021
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment 20% reducing balance
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs.
Functional and presentation currency
The financial statements of the company are measured and presented in the currency of the primary economic environment in which the company operates, the functional currency. The financial statements are presented in Pound sterling (£), which is the company’s functional currency.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current period.
2 Employees 2021 2020
Number Number
Average number of persons employed by the company 2 2
3 Tangible fixed assets
Fixtures, fittings, tools and equipment
£
Cost
At 1 May 2020 2,803
Additions 364
At 30 April 2021 3,167
Depreciation
At 1 May 2020 1,337
Charge for the year 366
At 30 April 2021 1,703
Net book value
At 30 April 2021 1,464
At 30 April 2020 1,466
4 Debtors 2021 2020
£ £
Other debtors 429 -
5 Creditors: amounts falling due within one year 2021 2020
£ £
Trade creditors 4,518 122
Corporation tax 8,227 7,564
Other taxes and social security costs 24 1,398
Other creditors 49 1
12,818 9,085
6 Related party transactions
The director and his wife are the only related parties. They have taken salaries and dividends which are disclosed in the accounts.
7 Controlling party
The director does not consider there to be an ultimate controlling party.
8 Other information
Cutting-Edge Therapeutics Limited is a private company limited by shares and incorporated in England. Its registered office is:
Suite 4, Cranbrook House
61 Cranbrook Road
Ilford
Essex
IG1 4PG
Cutting-Edge Therapeutics Limited 10146338 false 2020-05-01 2021-04-30 2021-04-30 VT Final Accounts April 2021 Zahid Sattar No description of principal activity 10146338 2019-05-01 2020-04-30 10146338 core:WithinOneYear 2020-04-30 10146338 core:ShareCapital 2020-04-30 10146338 core:RetainedEarningsAccumulatedLosses 2020-04-30 10146338 2020-05-01 2021-04-30 10146338 bus:PrivateLimitedCompanyLtd 2020-05-01 2021-04-30 10146338 bus:AuditExempt-NoAccountantsReport 2020-05-01 2021-04-30 10146338 bus:Director40 2020-05-01 2021-04-30 10146338 2 2020-05-01 2021-04-30 10146338 core:PlantMachinery 2020-05-01 2021-04-30 10146338 countries:England 2020-05-01 2021-04-30 10146338 bus:FRS102 2020-05-01 2021-04-30 10146338 bus:FullAccounts 2020-05-01 2021-04-30 10146338 2021-04-30 10146338 core:WithinOneYear 2021-04-30 10146338 core:ShareCapital 2021-04-30 10146338 core:RetainedEarningsAccumulatedLosses 2021-04-30 10146338 core:PlantMachinery 2021-04-30 10146338 2020-04-30 10146338 core:PlantMachinery 2020-04-30 iso4217:GBP xbrli:pure